SEL 403

Drug Profile

SEL 403

Alternative Names: LMB 100/SVP Rapamycin; SEL-403; SVP Rapamycin/LMB 100

Latest Information Update: 14 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Selecta Biosciences
  • Class Anti-infectives; Antifungals; Antineoplastics; Immunotoxins; Lactones; Macrolides; Polyenes; Proteins; Pyridines; Recombinant fusion proteins
  • Mechanism of Action Immunosuppressants; Megakaryocyte potentiating factor inhibitors; Methylmalonyl CoA mutase stimulants; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Mesothelioma

Most Recent Events

  • 28 Feb 2018 Phase-I clinical trials in Mesothelioma (Second-line therapy or greater, In adults, In the elderly) in USA (Parenteral) (NCT03436732)
  • 02 Jan 2018 Selecta Biosciences in collaboration with the National Cancer Institute plans a dose escalating phase I trial of SEL 403 for Mesothelioma (Second-line therapy or greater, In adults, In the elderly) in USA in the first quarter of 2018
  • 02 Jan 2018 Selecta Biosciences establishes CRADA with National Cancer Institute for the phase I development of SEL-403 in Mesothelioma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top